PRESS RELEASE
Utrecht and London, 17 March 2026
GenDx, a Eurobio Scientific Company, based in the Netherlands, specialized in molecular diagnostics for transplantation, today announced a collaboration with Treos Bio, a UK based clinical stage
company, developing next generation of effective off-the-shelf peptide cancer immunotherapies. GenDx and Treos Bio will partner in the development and validation of an integrated companion
diagnostic (CDx) HLA-typing test for Treos Bio’s off-the-shelf peptide cancer immunotherapy candidate, PolyPEPI1018, for the treatment of microsatellite stable (MSS) colorectal cancer.
The companion diagnostic (CDx) will combine GenDx’s IVDR registered NGSgo® HLA-A, HLA-B and HLA-C typing kits and NGSengine® analysis software with Treos Bio’s proprietary PEPI Test predictive software platform in compliance with ISO13485, IVDR and relevant U.S. FDA regulatory requirements. The integrated HLA typing workflow and PEPI Test predictive software are planned
to be clinically validated during Treos Bio’s anticipated phase 3 clinical trial of PolyPEPI1018.
This long-term partnership brings together GenDx’s deep IVD and regulatory knowledge and expertise with Treos Bio’s predictive immunology platform and innovative cancer immunotherapies. The collaboration aims to accelerate the clinical development of Treos Bio’s active immunotherapies while enabling precise patient selection through an integrated companion diagnostic approach.
Maarten Penning, PhD General Manager of GenDx, commented:
“I am very pleased that GenDx enters a companion diagnostics collaboration with Treos Bio. Our years-long expertise in HLA-typing for the transplant field, presents a solid-base to expand our portfolio into the field of HLA-CDx, allowing for further improving quality of life and survival of patients.”
Eniko R. Toke, PhD Chief Scientific Officer of Treos Bio, commented:
“This collaboration represents an important step toward integrating precision diagnostics with next-generation immunotherapy. By combining GenDx’s HLA typing technology with Treos Bio’s PEPI Test predictive software, we aim to translate our predictive immunology approach into clinical practice — identifying patients most likely to benefit from PolyPEPI1018 while advancing a more precise and scalable approach to active cancer immunotherapies.”
About HLA
The Human Leukocyte Antigen (HLA) system comprises a highly diverse family of genes and allelic variants that play a central role in the human immune response by presenting peptide antigens to T cells. Variability in HLA alleles determines which antigens can be presented to the immune system and therefore impacts immune recognition. High-resolution HLA typing enables the identification of specific nucleotide sequences and is widely used in transplantation diagnostics and increasingly in precision immunotherapies.
About PolyPEPI1018
PolyPEPI1018 is an investigational off-the-shelf peptide immunotherapy designed to activate broad, tumor-specific T cell responses across diverse patient populations. The vaccine contains a set of rationally selected tumor-associated peptides predicted to generate multiple CD8+ and CD4+ T cell epitopes (PEPIs) that can be presented by a broad set of HLA alleles. By targeting antigens frequently expressed in tumors while prioritizing peptides with a high likelihood of immunogenicity in individual patients, PolyPEPI1018 aims to overcome the limitations of conventional shared antigen vaccines and provide personalized-like immune coverage without the need for tumor sequencing or bespoke manufacturing.
To further optimize patient selection, Treos Bio is co-developing a companion diagnostic based on HLA class I genotyping that is intended to identify patients most likely to respond to the therapy. This strategy combines an off-the-shelf immunotherapy with precision biomarker guidance, enabling a scalable yet patient-tailored approach to cancer immunotherapy.
About PEPI Test
The PEPI Test is Treos Bio’s proprietary predictive software platform designed to analyze individual HLA genotypes and predict immune responses to vaccine epitopes. By identifying epitopes capable of binding multiple HLA molecules within the same patient, the PEPI Test supports selection of vaccine targets with a high probability of inducing broad T cell responses. In combination with GenDx’s high resolution HLA typing workflow, the PEPI Test forms the basis of an integrated companion diagnostic intended to guide patient selection for PolyPEPI1018 and future PEPI-based cancer vaccines.
About GenDx, a Eurobio Scientific Company
Genome Diagnostics B.V., trading as GenDx, is a Dutch company specializing in molecular diagnostics. It focuses on the development, production, and sale of innovative assays and analysis software for transplantation and companion diagnostics. GenDx offers a range of HLA sequencing based typing strategies, reagents, software, and custom laboratory services. GenDx Education also provides dedicated training courses worldwide for professionals in tissue typing, research laboratories, blood banks, and donor registries. As a strong CDx partner with years of IVD expertise, GenDx supports precision medicine development programs through tailored CDx services, facilitating clinical study validation and easing regulatory landscape navigation, contributing to the success of a pharmaceutical therapy.
In October 2022, Eurobio Scientific acquired all shares of GenDx. For more information, visit GenDx.com.
About Eurobio Scientific
Eurobio Scientific is a major player in the field of specialty in vitro diagnostics. It is involved in everything from research to the marketing of diagnostic tests in the fields of transplantation, immunology, and infectious diseases, and offers reagents for research laboratories, including pharmaceutical and biotechnology companies. With its numerous partnerships and strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary products. The Group has approximately 300 employees, four production units based in France (the Paris region), Germany, the Netherlands, and the United States, and (distribution) subsidiaries in Italy; Great Britain; Switzerland; Belgium and Australia. Eurobio Scientific’s reference shareholder is the holding company EB Development, acting in concert with funds managed by NextStage AM and IK Partners, as well as members of the Company’s Board of Directors and senior management.
For further information, visit: www.eurobio-scientific.com
Eurobio Scientific shares are listed on Euronext Growth Paris.
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising
Tech label. Ticker symbol: ALERS – ISIN code: FR0013240934 – Reuters: ALERS.PA – Bloomberg:
ALERS:FP
About Treos Bio
Treos Bio is a clinical-stage biotechnology company developing precision peptide immunotherapies designed to harness the power of the immune system to treat cancer. The company’s approach combines computational immunotherapy design with deep immunogenomic insights to identify tumor antigens most likely to generate effective T cell responses across diverse patient populations.
Treos Bio’s proprietary PASCal (Personal Antigen Selection Calculator) technology platform integrates tumor antigen expression data, HLA genotype-based immunogenicity prediction, and population-scale immune modelling to identify peptides that are highly immunogenic in individual patients. The company’s lead program, PolyPEPI1018, is an off-the-shelf multi-peptide immunotherapy targeting shared tumor antigens with demonstrated clinical activity in MSS colorectal cancer.
For more information, visit www.treosbio.com.
GenDx
Yalelaan 48
3584 CM Utrecht
The Netherlands
Office: +31 30 252 3799
E-mail: info@gendx.com
Contact GenDx: Hanneke Merkens PhD, Chief Marketing Officer GenDx
Email: h.merkens@gendx.com
NGSgo®, NGSengine® and GenDx are registered trademarks of Genome Diagnostics B.V.
Treos Bio
1st Floor
40-44 Newman Street
London W1T 1QD
United Kingdom
E-mail: IR@treosbio.com
